Heartflow Q2 Revenue Jumps 48%, Raises Full-Year Guidance
HTFL sits 58% above its 52-week low of $20.13.
Summary
Heartflow reported Q2 revenue of $64.1M, up 48% YoY, and raised full-year guidance to $246-$250M. Gross margin expanded to 83% and cash stands at $246.8M.
Key Events · Earnings and Guidance · HTFL
-
Q2 Revenue Up 48%
Total revenue reached $64.1 million, a 48% increase year-over-year, driven by higher FFR CT and Plaque case volumes.
-
Full-Year Guidance Raised
Management raised 2026 revenue guidance to $246-$250 million (40-42% growth) from $228-$232 million, and non-GAAP gross margin guidance to ~82% from ~81%.
-
Gross Margin Expansion
Gross margin improved to 83.0% from 75.5% a year ago, reflecting higher case volume and AI-driven productivity gains.
-
Loss Narrows on Non-GAAP Basis
Non-GAAP net operating loss narrowed to $7.9 million from $11.5 million; GAAP net loss was $15.7 million ($0.18/share).
Analysis · HTFL · Industrial Applications And Services
A standout quarter for Heartflow, with revenue climbing 48% year-over-year to $64.1 million on the back of higher FFR CT and Plaque case volumes. Management lifted full-year revenue guidance to $246-$250 million, implying 40-42% growth, up from the prior $228-$232 million range. Gross margin expanded to 83.0% from 75.5% a year ago, and the non-GAAP operating loss narrowed to $7.9 million from $11.5 million. The company remains unprofitable on a GAAP basis with a net loss of $15.7 million, but holds $246.8 million in cash and investments, providing ample runway. This is a notable positive update for a company that has seen consistent insider selling over the past 90 days.
At the time of this filing, HTFL was trading at $31.78 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $20.13 to $41.22. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.